Gene Therapy for Corneal Diseases
BioTech · 22.09.2026 · 15 (4) · 80
DOI: 10.3390/biotech15040080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioTech, online erschienen am 22.09.2026. Verfasst von Basanta Bhujel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 291 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ACL HHS, Asan Institute for Life Sciences, National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Corneal diseases are a major cause of blindness and visual impairment worldwide. Although conventional pharmacological therapies can alleviate mild to moderate corneal disorders, they often fail to restore vision in advanced disease, leaving corneal transplantation as the current standard treatment. However, donor tissue shortages, graft rejection, and surgical complications continue to limit its long-term success, highlighting the urgent need for effective nonsurgical therapeutic strategies. Gene therapy has emerged as a promising approach for treating inherited and acquired corneal diseases by targeting the underlying molecular mechanisms that drive disease progression. Recent advances in genome-editing technologies, gene-delivery systems, and vector engineering have substantially expanded the clinical potential of gene-based interventions. This review summarizes current progress in gene-editing strategies, gene-delivery platforms, and their therapeutic applications across a broad spectrum of corneal diseases. In addition, we discuss the major challenges and future perspectives associated with delivery efficiency, safety, vector optimization, and clinical translation. Collectively, these advances highlight the potential of gene therapy to transform the management of corneal diseases by providing safe, targeted, and long-lasting therapeutic strategies for restoring corneal function and vision.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
ORCID-Profile: Basanta Bhujel, Kyu Sang Eah, Ho Seok Chung, Jae-Yong Kim
Förderung
- ACL HHS
- Asan Institute for Life Sciences
- National Research Foundation of Korea (NRF)
- Basic Science Research Program through the National Research Foundation of Korea
- Ministry of Education, Science, and Technology
- Asan Institute for Life Sciences, Seoul, Republic of Korea
Zitieren
APA
Bhujel, B., Eah, K. S., Kang, S. S., Chung, H. S., & Kim, J. Y. (2026). Gene Therapy for Corneal Diseases. BioTech, 15(4), 80. https://doi.org/10.3390/biotech15040080
Vancouver
Bhujel B, Eah KS, Kang SS, Chung HS, Kim JY. Gene Therapy for Corneal Diseases. BioTech. 2026;15(4):80. doi:10.3390/biotech15040080
BibTeX
@article{Bhujel2026,
author = {Bhujel, Basanta and Eah, Kyu Sang and Kang, Soon Suk and Chung, Ho Seok and Kim, Jae-Yong},
title = {Gene Therapy for Corneal Diseases},
journal = {BioTech},
year = {2026},
volume = {15},
number = {4},
pages = {80},
doi = {10.3390/biotech15040080}
}
EUVIMED